Elucidating Prostate Cancer Behaviour During Treatment via Low-pass Whole-genome Sequencing of Circulating Tumour DNA
Semini Sumanasuriya(Institute of Cancer Research), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Jane Goodall, Mario A. Eisenberger(Johns Hopkins University), Pasquale Rescigno(Institute of Cancer Research), Wei Yuan(Shanghai Public Health Clinical Center), Antje Neeb(Institute of Cancer Research), Mustapha Chadjaa(Sanofi (France)), Harry Parr(University of London), Christine Geffriaud-Ricouard(Sanofi (France)), Niven Mehra(Royal Marsden NHS Foundation Trust), Joaquı́n Mateo(Royal Marsden NHS Foundation Trust), Penelope Flohr(Royal Marsden NHS Foundation Trust), Joe Baxter(Institute of Cancer Research), Rossitza Christova(Institute of Cancer Research), Jan Rekowski(Institute of Cancer Research), Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Gemma Fowler, Adam Sharp(Institute of Cancer Research), Ayse Ӧzatılgan(Sanofi (France)), Oliver Sartor(Mayo Clinic), Sandrine Macé(Sanofi (France)), Suzanne Carreira(Institute of Cancer Research), Stephen J. Pettitt(Gene Therapy Laboratory), Lorna Pope(Institute of Cancer Research), Christopher J. Lord(Institute of Cancer Research), Diletta Bianchini(Royal Marsden NHS Foundation Trust), Ines Figueiredo(Institute of Cancer Research), Cláudia Bertan(Institute of Cancer Research), Maryou Lambros(Institute of Cancer Research), George Seed(Institute of Cancer Research)
Cited by 65
Related Papers
Alpha Emitter Radium-223 and Survival in Metastatic Prostate Cancer
|New England Journal of Medicine|2013|3.3k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer
|New England Journal of Medicine|2015|2.8k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k